Harmony Biosciences Holdings, Inc. (HRMY) announced that Glenn Reicin will assume the role of Chief Financial Officer effective April 14, 2026. Reicin brings a decade‑plus track record in biopharmaceutical finance, having served as CFO at Eccogene and Alladapt Immunotherapeutics, and a 15‑year tenure as a top‑ranked research analyst at Morgan Stanley. His compensation package includes a $500,000 annual base salary, a target annual bonus of 50% of salary, and a $3,000,000 stock option grant vesting over four years.
"Glenn's experience leading organizations through periods of growth and transformation will be instrumental as we look to execute on our strategy with a focus on bringing innovative treatments to patients with unmet medical needs and creating even greater value for our shareholders," said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences.
"I am excited to welcome Glenn to Harmony and his appointment comes at a pivotal moment in the evolution of the company, as we look to leverage our strong balance sheet to grow the enterprise and drive long‑term value creation," added Dayno.
Harmony reiterated its 2026 net product revenue guidance for its flagship narcolepsy drug WAKIX, projecting $1.0 to $1.04 billion in net product revenue. The guidance aligns with the company’s trajectory of consistent growth, following a 21% year‑over‑year increase in Q4 2025 net product revenue to $243.8 million and a full‑year 2025 net product revenue of $868.5 million.
The company’s robust financial position is underscored by a strong balance sheet and self‑funding capability, while its late‑stage pipeline—featuring multiple Phase 3 trials—positions it for future expansion. The appointment of Reicin is expected to reinforce financial stewardship and support the company’s strategic initiatives.
Market reaction to the announcement was positive, driven primarily by the experienced new CFO and the reaffirmation of the 2026 revenue guidance, signaling confidence in Harmony’s continued growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.